Evidence map›Paper›PMID 39582148›Full record

ArticleCancer communications (London, England)2025

PTPN9 regulates HER3 phosphorylation during trastuzumab treatment and loss of PTPN9 is a potential biomarker for trastuzumab resistance in HER2 positive breast cancer.

Abul Azad, Maryam Arshad, Daniele Generali, Katharina Feldinger, Merel Gijsen, Carla Strina, Mariarosa Cappelletti, Daniele Andreis, Russell Leek, Syed Haider and 6 more

Abstract readLetter
PubMed Full text at PMC Publisher
In one paragraph

Article in Cancer communications (London, England), 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 3 papers.

0numbers the graph read from it
0cells of the map it votes in
3citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

3 citing papers in PubMed.

  1. Article
  2. PTPN9 dephosphorylates IGF1RJournal of experimental & clinical cancer research : CR · 2025
    Article
  3. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

16 authors.

Abul AzadDepartment of Oncology, The Weatherall Institute of Molecular Medicine, University of Oxford, Oxford, UK.
Maryam ArshadInstitute of Genomic and Cancer Sciences, Vincent Drive, University of Birmingham, Birmingham, UK.
Daniele GeneraliU.O. Multidisciplinare di Patologia Mammaria, U.S Terapia Molecolare e Farmacogenomica, A.O. Instituti Ospitalieri di Cremona, Viale Concordia 1, Cremona, Italy.
Katharina FeldingerDepartment of Oncology, The Weatherall Institute of Molecular Medicine, University of Oxford, Oxford, UK.
Merel GijsenDepartment of Oncology, The Weatherall Institute of Molecular Medicine, University of Oxford, Oxford, UK.
Carla StrinaU.O. Multidisciplinare di Patologia Mammaria, U.S Terapia Molecolare e Farmacogenomica, A.O. Instituti Ospitalieri di Cremona, Viale Concordia 1, Cremona, Italy.
Mariarosa CappellettiU.O. Multidisciplinare di Patologia Mammaria, U.S Terapia Molecolare e Farmacogenomica, A.O. Instituti Ospitalieri di Cremona, Viale Concordia 1, Cremona, Italy.
Daniele AndreisU.O. Multidisciplinare di Patologia Mammaria, U.S Terapia Molecolare e Farmacogenomica, A.O. Instituti Ospitalieri di Cremona, Viale Concordia 1, Cremona, Italy.
Russell LeekDepartment of Oncology, The Weatherall Institute of Molecular Medicine, University of Oxford, Oxford, UK.
Syed HaiderDepartment of Oncology, The Weatherall Institute of Molecular Medicine, University of Oxford, Oxford, UK.
Pirkko-Liisa Kellokumpu-LehtinenDepartment of Oncology, Tampere University Hospital and Tampere University, Tampere, Finland.
Ioannis RoxanisThe Institute of Cancer Research, London, UK.
Adrian Llewellyn HarrisDepartment of Oncology, The Weatherall Institute of Molecular Medicine, University of Oxford, Oxford, UK.
Abeer Mahmoud ShaabanDepartment of histopathology, Queen Elizabeth Hospital Birmingham, Birmingham, UK.
Heikki JoensuuDepartment of Oncology, Helsinki University Hospital and University of Helsinki, Helsinki, Finland.
Anthony KongDepartment of Oncology, The Weatherall Institute of Molecular Medicine, University of Oxford, Oxford, UK.ORCID https://orcid.org/0000-0002-3989-3948

Funding

Breakthrough Breast Cancer CSF-Kong
6 · The paper itself

Abstract

PubMed holds no abstract for this paper.

Identifiers

PMID39582148
PMCPMC11758155

What Socratic holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the Socratic graph.